Sentences with phrase «therapies than patient»

In a retrospective analysis of clinical trial data, they found that melanoma patients with highly aneuploid tumors were less likely to benefit from immune checkpoint blockade therapy than patients whose tumors showed fewer chromosomal disruptions.

A University of Colorado Cancer Center study published in the journal Breast Cancer Research and Treatment shows that breast cancer patients whose health insurance plans included prescription drug benefits were 10 percent more likely to start important hormonal therapy than patients who did not have prescription drug coverage.

Not exact matches

One setback for these therapies which use the body's immune system to fight cancers is that they are, at times, more effective in certain patient pools than others.

Amgen unveiled some promising news during the American Heart Association's annual meeting involving its next - gen cholesterol - busting medication Repatha, which has been shown to significantly reduce the level of «bad» cholesterol in patients, announcing that more than 60 % of patients who were receiving the therapy in a trial had a reduction in arterial plaque.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Satwani — who hasn't delivered the CAR - T therapy but is heading up the program at Columbia, one of the 32 sites Novartis will use — said patients would need to be monitored closely for about a month, meaning they'd need to be less than a two - hour drive from their hospital.

REINVENTING THE CLINICAL TRIAL Research Track Traditional clinical trials ask one question: Does an experimental treatment work better than nothing at all — or, the very least, the standard therapy offered patients.

This week, Sanofi and Regeneron struck a deal with Express Scripts in which they'll more than halve the price of their therapy in exchange for an easier path to patients.

Dr. Newman added that rival CAR T cell therapy developer Kite Pharma was still likelier to generate more revenue than Juno with KTE - C19, which last week completed patient enrollment in the Phase II portion of the ZUMA - 1 trial in patients with diffuse large B - cell lymphoma.

About Memorial Sloan - Kettering Cancer Center: The world's oldest and largest private cancer center, Memorial Sloan - Kettering Cancer Center (MSKCC) has devoted more than a century to patient care as well as to innovative research, making significant contributions to new and better therapies for the treatment of cancer.

We've served over 600,000 hypnosis downloads and treated more than 5,000 patients in 1:1 therapy.

After almost three months of medication and talk therapy, I'm feeling better than I can remember; I'm patient, loving, and grateful for my son, and am able to see pregnant women and babies without crying.

Despite complications sometimes more severe than with standard radiation therapy — and costs that are much higher for taxpayers, patients and insurers — proton beam therapy is heavily marketed for treatment of prostate cancer.

Partly because of a marketing push, prostate cancer patients have flocked to proton therapy despite the lack of evidence that it's better than less expensive treatment.

Minimally conscious patients are more likely to recover than those in a VS and so receive different therapies.

Redberg says observational data — which follow real - world patients on statin therapy — report side effect risks much higher than those in the CTT analyses.

«Our research indicates that insertion of cervical pessary at around 22 weeks in both randomly selected women pregnant with twins and in patients with a short cervix of less than 25 millimeters does not reduce the rate of spontaneous early preterm birth, perinatal death, adverse neonatal outcome, or need for neonatal therapy.»

Type 2 diabetes afflicts more than 300 million people globally, and as many as 15 % of those patients can not take the first - line therapy metformin because of kidney damage risks.

But success could leave a lasting mark on cancer care, by helping hundreds of thousands of patients every year, far more than other genetically targeted therapies.

The machine - learning program predicted which patients would fail to respond to cognitive behavioral therapy with 70 percent accuracy, significantly better than chance, or 50 percent.

Among the patients not given a choice of treatment, counseling with prolonged exposure therapy cost on average slightly less than pharmacotherapy with sertraline — $ 7,030 versus $ 8,650 per patient per year.

Another strategy, which Steinman and others were studying, involves a therapy to target dendritic cells inside the body rather than taking them out and personalizing therapy for each patient.

«If it isn't possible to allow patients to choose, prolonged exposure therapy rather than the medication is a cost - effective treatment option,» Zoellner said.

The fact that TAS - 102 temporarily halted the disease in many of these patients suggests that it operates through a different biochemical pathway than 5 - FU, and therefore may serve as an alternative to standard therapy.

If all goes well (a big if in Alzheimer's research), a therapy targeting the enzyme could be available to patients in less than a decade.

«This greater than expected survival in older patients selected for operative therapy is noteworthy,» said Dr. Fernandez, «especially considering that the prevalence of lung cancer is expected to increase as the population continues to grow older and more people survive into old age.»

Patients included had experienced symptoms of tennis elbow for more than 6 months, and attempted at least two non-surgical treatment approaches such as physical therapy, massage, acupuncture, or splinting / bracing, but had no symptom relief over that period.

Lead investigator, Evan Matros, MD, FACS, explained that today plastic surgeons are more willing to perform reconstructive procedures in these patient groups — which include women age 65 and older or those who have had radiation therapy — than they were 15 years ago, and that patients themselves are more accepting of these reconstruction procedures.

This episode highlights a growing challenge for patients: how to temper enthusiasm for experimental therapies, now widely and effectively marketed through personal testimonials posted online, until evidence shows that the treatments are likely to do more good than harm.

Patients who got it lived about 4 months longer, nearly 26 months total, than those who didn't — but that, say company executives, is still more than any other therapy has managed for this disease in a randomized trial.

«Patients more likely to refuse drug therapy than psychotherapy for mental health: Individuals already on drug therapy also more likely to discontinue treatment early, study says.»

But for some patients who have received therapy and survived, the risk of dying from the side effects over the long term might be even higher than from the cancer.

This study used the National Cancer Data Base to analyze 9,817 patients and found that patients treated at higher - volume facilities were more likely to have shorter radiation therapy duration than those at lower volume facilities.

«Although some non-small cell lung cancer patients have increased benefit of targeted therapy or immunotherapy instead of chemotherapy, for some groups of patients with NSNSCLC, chemotherapy has been the standard treatment for more than 30 years,» Gandhi notes.

«It's a method that is much more feasible and safer for patients than traditional gene therapy, which uses modified viruses to carry out the treatment.»

Researchers from Massachusetts Eye and Ear / Harvard Medical School have found that patients who were prescribed corticosteroids as part of treatment for Lyme disease - associated facial paralysis had worse long - term outcomes of regaining facial function than those who were prescribed antibiotic therapy alone.

While the patient eventually relapsed and died more than a year after CAR T - cell therapy, the brain tumor never recurred.

Patients in the clinical trial who got the combined therapies also had fewer serious adverse side effects than those who received only ipilimumab, the researchers report in the Journal of the American Medical Association.

In Cohort B — those who received pembrolizumab as first - line therapy — 12 of 52 patients, or 23 percent, saw tumors shrink by more than 30 percent, while the disease was stabilized in nine of them, or 17 percent.

An international study involving Manchester researchers has found that for previously untreated lung cancer patients with a particular genetic change, a new targeted therapy is better than standard chemotherapy.

Although abnormal ALK is found in only about 5 percent of NSCLC cases, that translates into more than 5,000 new patients annually who could potentially benefit from crizotinib therapy, the study authors state.

In terms of clinical practice, physicians can use risk assessment tools in some cases to determine which patients would most likely benefit from statin therapy, rather than focusing only on blood cholesterol to determine which patients would benefit.

«Sometimes, drug therapies bring more issues than relief for these patients,» Dr. Ron said.

They also added that BRAF - mutant melanoma patients with a family history of colorectal cancer may require more than the usual screening if BRAF - inhibitor therapy is necessary.

«Moreover, if a patient is already on a systemic drug but is experiencing a flare in a limited number of joints, we could specifically treat these joints rather than switching systemic therapy or adding another systemic drug.

Analyzing more than 120 million patient records and identifying trends of co-occurrence among hundreds of diseases, they created a unique genetic map that has the potential to guide researchers and clinicians in diagnosing, identifying risk factors for and someday developing therapies against complex diseases.

Rather than surrendering to despair and impersonal medical treatments, growing numbers of cancer patients are empowering themselves with information and control over their therapies.

Regardless of disease stage, patients who received surgery lived an average of 57 months, compared to less than 12 months for patients who received only non-surgical treatment (such as chemotherapy or radiation therapy), and 1.4 months for patients who received no treatment at all.

The studies included almost 10,000 patients aged 62 to 84 years old who were followed up for anywhere from a year to more than six years after their therapy ended.

«While there is understandable excitement around new therapies that enlist the immune system to fight cancer, we are still in a situation where greater than half of patients don't respond in melanoma and the response rate is even worse in other cancer types,» Hanks said.